Diagnosis and therapy of cancer involving cancer stem cells

Patent metadata

Field	Value
Publication number	US-10604568-B2
Application number	US-201414904011-A
Country	US
Kind code	B2
Filing date	Jul 30, 2014
Priority date	Jul 31, 2013
Publication date	Mar 31, 2020
Grant date	Mar 31, 2020

Abstract

The present invention provides methods for diagnosis or treatment of cancer diseases involving cancer stem cells comprising targeting CLDN6. In particular, the present invention provides a method of determining cancer stem cells comprising detecting cells expressing CLDN6, Furthermore, the present invention provides a method of treating or preventing cancer comprising inhibiting and/or eliminating cancer stem cells by administering an antibody having the ability of binding to CLDN6 to a cancer patient.

First claim

The invention claimed is:

1. A method of treating cancer comprising:
administering to a cancer patient identified as having ovarian cancer characterized by chemoresistant cancer cells expressing CLDN6 an antibody drug conjugate that binds to CLDN6, wherein the antibody drug conjugate comprises a heavy chain variable region (VH) of SEQ ID NO: 5 and a light chain variable region (VL) of SEQ ID NO: 4 and at least one toxin drug moiety that targets microtubules selected from N2′-deacetyl-N2′(3-mercapto-1-oxopropyl)-maytansine (mertansine or DM1) and monomethyl auristatin E (MMAE).

2. The method of claim 1 wherein the antibody drug conjugate comprises a cleavable linker between the antibody and the at least one toxin drug moiety.

3. The method of claim 1 further comprising administering radiation therapy.

4. The method of claim 2 wherein the cleavable linker is cleavable by a cathepsin.

5. A method of treating a cancer patient having a chemoresistant cancer selected from the group consisting of ovarian cancer, testicular cancer, uterine cancer, germ cell tumors, gastric cancer, and metastatic forms thereof, the method comprising administering to the cancer patient, an antibody drug conjugate that binds to CLDN6, wherein the antibody drug conjugate comprises a heavy chain variable region (VH) of SEQ ID NO: 5 and a light chain variable region (VL) of SEQ ID NO: 4 and at least one toxin drug moiety that targets microtubules selected from N2′-deacetyl-N2′(3-mercapto-1-oxopropyl)-maytansine (mertansine or DM1) and monomethyl auristatin E (MMAE), wherein the cancer is characterized by cancer cells expressing CLDN6.

6. The method of claim 5 which further comprises administering radiation therapy.

7. The method of claim 5 wherein the antibody drug conjugate comprises a cleavable linker between the antibody and the at least one toxin drug moiety.

8. The method of claim 7 wherein the cleavable linker is cleavable by a cathepsin.

9. The method of claim 5 wherein,
when the cancer is a germ cell tumor, the germ cell tumor is selected from the group consisting of teratocarcinoma, embryonal carcinoma, tumors of the testis, and tumors of the ovary; and
when the cancer is testicular cancer, the testicular cancer is selected from the group consisting of testicular seminoma, testicular teratoma and testicular embryonal carcinoma.

10. The method of claim 5 , wherein the cancer is ovarian cancer.

Assignees

• Biontech Ag
• Astellas Pharma Inc
• Tron Translationale Onkologie An Der Univ Johannes Gutenberg Univ Mainz Gemeinnuetzige Gmbh
• BioN Tech AG
• Tron Translationale Onkologie An Der Univ Der Johannes Gutenberg Univ Mainz Gemeinnuetzige Gmbh

Inventors

• Sahin Ugur
• Tureci Ozlem
• Walter Korden
• Wagner Meike
• Kreuzberg Maria
• Hacker Sabine
• Jacobs Stefan

Classifications

• C07K16/30

  from tumour cells · CPC title

• C07K2317/56

  variable (Fv) region, i.e. VH and/or VL · CPC title

• A61K47/6851

  the antibody targeting a determinant of a tumour cell · CPC title

• A61K31/7064

  containing condensed or non-condensed pyrimidines · CPC title

• C07K2317/732

  Antibody-dependent cellular cytotoxicity [ADCC] · CPC title